any feedback welcome, page-3

Hi TDA,

You are loaded up and have done your own research so I'm guessing you are well appraised of the pros and cons, and would also appreciate there's risk with every investment. Given the road they have travelled to reach this critical stage in the company's development, Alan Shortall and the team understand this better than anyone and have gone to great lengths to mitigate the risk on the prefill and 1ml syringe projects. For example, the latest update confirmed that all marketing and distribution costs will be borne by their partners. Previous updates spell out other initiatives to de-risk these two projects as much as possible.

I recently asked Alan Shortall what could go wrong. I was less concerned with manufacturing glitches and more concerned about a back-up plan should the current negotiations not reach a successful conclusion. My impression was that he was confident this would not happen. I have mentioned on a previous thread that Unilife's technology is a genuinely disruptive technology in that it fundamentally changes the way something is done. This applies not only to the design and functionality of the Unitract syringes themselves but also the way the drug is delivered, i.e. prefill v. vial. The days of a doctor using a syringe to extract a visual measure of drug from a vial are all but over. Prefill is the future and Unilife is at the vanguard of this development. Another vital factor to bear in mind, as explained in recent updates, is that the Unilife prefill technology seamlessly integrates with the Pharma's current manufacturing processes. Thus there are minimal disruption in terms of getting manufacturing up and running. This was an especially big concern of the Pharma, and it has been overcome by Unilife's own systems.

Remember also that big Pharma approached Unilife about the Unitract syringe, not the other way round. They want it. This puts Unilife in a very strong bargaining position.

Thus the high level of confidence that the negotiations will reach a successful conclusion is not misplaced, because the pharma partner does not want to let the opportunity to be a market leader slip from their grasp. There are plenty of other competitors and potential partners for Unilife who would gladly take a seat at the negotiating table. Given that Gerresheimer are the number two manufacturer of prefills in the world, and the pharma partner are somewhere in the top ten, probabaly top five, the stakes are enormous for all concerned.

By definition, when all parties to a negotiation have a vested interest in the negotiations succeeding, the negotiations themselves have the best possible chance of a successful outcome. While this is a company-making deal for Unilife, it also assure their partner's leadership in this emerging market. A few weeks more will see it happen, but that's just my opinion.....